Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) on Friday, plunged -5.03% from the previous trading day, before settling in for the closing price of $21.69. Within the past 52 weeks, CPRX’s price has moved between $13.00 and $24.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 4106.79% over the last five years. The company achieved an average annual earnings per share of 88.89%. With a float of $102.92 million, this company’s outstanding shares have now reached $107.12 million.
The firm has a total of 167 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.23%, operating margin of 37.97%, and the pretax margin is 41.2%.
Catalyst Pharmaceuticals Inc (CPRX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Catalyst Pharmaceuticals Inc is 13.70%, while institutional ownership is 75.57%. The most recent insider transaction that took place on Nov 13 ’24, was worth 2,125,465. In this transaction Chairman of Board of Directors of this company sold 92,500 shares at a rate of $22.98, taking the stock ownership to the 4,478,169 shares. Before that another transaction happened on Nov 14 ’24, when Company’s Chairman of Board of Directors sold 44,655 for $21.75, making the entire transaction worth $971,336. This insider now owns 4,478,169 shares in total.
Catalyst Pharmaceuticals Inc (CPRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 88.89% per share during the next fiscal year.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Catalyst Pharmaceuticals Inc (CPRX) is currently performing well based on its current performance indicators. A quick ratio of 4.92 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.07. Likewise, its price to free cash flow for the trailing twelve months is 12.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.17, a number that is poised to hit 0.32 in the next quarter and is forecasted to reach 1.51 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Analysing the last 5-days average volume posted by the [Catalyst Pharmaceuticals Inc, CPRX], we can find that recorded value of 1.42 million was better than the volume posted last year of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 22.60%. Additionally, its Average True Range was 0.80.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 60.58%, which indicates a significant increase from 4.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.31% in the past 14 days, which was higher than the 37.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.99, while its 200-day Moving Average is $17.42. Now, the first resistance to watch is $21.34. This is followed by the second major resistance level at $22.08. The third major resistance level sits at $22.53. If the price goes on to break the first support level at $20.15, it is likely to go to the next support level at $19.70. Should the price break the second support level, the third support level stands at $18.96.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
Market capitalization of the company is 2.33 billion based on 119,273K outstanding shares. Right now, sales total 398,200 K and income totals 71,410 K. The company made 128,700 K in profit during its latest quarter, and 43,880 K in sales during its previous quarter.
